Trial reportScientific reports2016
Clinical features and management of multifocal hepatic hemangiomas in children: a retrospective study.
Trial report in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- A Comprehensive Review of Hepatic Hemangioma Management.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2022Pooled it
- Propranolol monotherapy versus propranolol plus prednisone for diffuse infantile hepatic haemangioma: a randomized clinical trial.World journal of pediatrics : WJP · 2026Trial
- Safety and tolerance of propranolol in neonates with severe infantile hemangiomas: a prospective study.Scientific reports · 2017Trial
- Life-Threatening Complications and Intensive Care of Diffuse Neonatal Hemangiomatosis of the Liver in a One-Month-Old Girl: A Case Report.Children (Basel, Switzerland) · 2026Article
- Clinical characteristics and managements of congenital hepatic hemangioma: a cohort study of 211 cases.Hepatology international · 2025Observational
- Complete regression of a huge fetal hepatic hemangioma with cardiac complication after atrioventricular septal repair: a case description and literature analysis.Quantitative imaging in medicine and surgery · 2025Article
- Akt3 activation by R-Ras in an endothelial cell enforces quiescence and barrier stability of neighboring endothelial cells via Jagged1.Cell reports · 2024Article
- Diffuse infantile hepatic hemangioma successfully treated with propranolol orally: a case report and literature review.Frontiers in oncology · 2024Article
- Infantile hepatic hemangiomas: looking backwards and forwards.Precision clinical medicine · 2022Review
- Infantile Hemangioma Treated with Propranolol Readmission Trends, Complications of Therapy, and Cost: A PHIS Database Study.International journal of pediatrics · 2022Article
- Pediatric Primary Hepatic Tumors: Diagnostic Considerations.Diagnostics (Basel, Switzerland) · 2021Review
- Infantile hepatic hemangioma: current state of the art, controversies, and perspectives.European journal of pediatrics · 2020Review
- Multifocal infantile haemangiomatosis with hepatic involvement: two cases and treatment management.Drugs in context · 2020Article
- Clinical and economic impact of surgery for treating infantile hemangiomas in the era of propranolol: overview of single-center experience from La Paz Hospital, Madrid.European journal of pediatrics · 2019Review
- Intolerable side effects during propranolol therapy for infantile hemangioma: frequency, risk factors and management.Scientific reports · 2018Article
- Consumptive hypothyroidism in a two months old infant secondary to hepatic haemangiomas.Sudanese journal of paediatrics · 2018Article
- Effects of Propranolol on Neurodevelopmental Outcomes in Patients with Infantile Hemangioma: A Case-Control Study.BioMed research international · 2018Article
- Quality of life in children with infantile hemangioma: a case control study.Health and quality of life outcomes · 2017Article
- Current perspectives on the optimal management of infantile hemangioma.Pediatric health, medicine and therapeutics · 2017Review
- Propranolol Monotherapy in Multifocal/Diffuse Infantile Hepatic Hemangiomas in Indian Children: A Case Series.Journal of clinical and experimental hepatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multifocal hepatic hemangioma (MHH) is a benign hepatic tumor that is commonly diagnosed in children with multiple cutaneous infantile hemangiomas (IHs). We present a review of all children with MHH at our institutions. Of the 42 patients, the median age at presentation of MHH was 2.5 months. Thirty-six (85.7%) patients had cutaneous IHs. Twelve (28.6%) patients were symptomatic at presentation. There was no significant association between the number of hepatic hemangiomas and the number of cutaneous IHs. Fourteen (33.3%) patients received some form of treatment for hepatic hemangiomas. The most common type of treatment was oral prednisone in 8 patients, followed by oral propranolol in 6 patients. Two patients were totally resistant to prednisone treatment. They died from congestive heart failure or respiratory distress and coagulopathy. Two patients with problematic facial IH were treated with intralesional triamcinolone injection. The remaining 26 patients were managed with imaging surveillance. On follow-up, all of the survivors had a favorable outcome. Our study suggests that the clinical features of MHH are variable. Our data emphasize the treatment strategy that aggressive treatment is indicated in symptomatic or progressive MHHs, whereas observation management of asymptomatic patients with a few small lesions is safe and appropriate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.